Synerkine Pharma is a developer of fusion proteins for the treatment of chronic pain.
Synerkine Pharma has raised $5.6M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Synerkine Pharma's investors include InnovationQuarter, Thuja Capital, Netherlands Enterprise Agency, Flerie Invest, Utrecht Health Seed Fund.
Synerkine Pharma is headquartered in Utrecht, The Netherlands.
Synerkine Pharma is a developer of fusion proteins for the treatment of chronic pain.
Synerkine Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synerkine Pharma — Funding & Investors." VCBacked, October 12, 2023, https://www.vcbacked.co/company/synerkine-pharma. Accessed August 1, 2026.
VCBacked. (2023). Synerkine Pharma — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/synerkine-pharma
{{cite web |title=Synerkine Pharma — Funding & Investors |url=https://www.vcbacked.co/company/synerkine-pharma |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated